@article{21a4b76e447141ac9bedb3d57eb4a295,
title = "Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan",
author = "Taro Kishi and Kenji Sakuma and Makoto Okuya and Yuki Matsuda and Nakao Iwata",
note = "Funding Information: We would like to thank Takeda Pharmaceutical Company Limited (Tokyo, Japan ?103-8668) for confirming the number of Japan phase 3 trials of vortioxetine. Funding Information: Drs Kishi, Sakuma, Okuya, Matsuda, and Iwata declare that they have no direct conflicts of interest relevant to this study. No grant support or other sources of funding were used to conduct this study or prepare this manuscript. Dr Kishi has received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Kyowa, Otsuka, Pfizer, Meiji, MSD, Sumitomo Pharmaceuticals (Suzhou), Yoshitomi, and Tanabe‐Mitsubishi and has received a Health Labour Sciences Research Grant, Grant‐in‐Aid for Scientific Research (C), and a Fujita Health University School of Medicine research grant. Dr Sakuma has received speaker's honoraria from Otsuka and Meiji. Dr Okuya has received speaker's honoraria from Meiji. Dr Matsuda has received speaker's honoraria from Dainippon Sumitomo, Eisai, Eli Lilly, GlaxoSmithKline, Otsuka, Tanabe‐Mitsubishi, and Pfizer and has received a grant‐in‐aid for Young Scientists (B). Dr Iwata has received speaker's honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, GlaxoSmithKline, Janssen, Yoshitomi, Otsuka, Meiji, Shionogi, Novartis, and Pfizer and has had research grants from Dainippon Sumitomo, Eisai, Daiichi Sankyo, GlaxoSmithKline, Meiji, and Otsuka.",
year = "2020",
month = may,
day = "1",
doi = "10.1111/pcn.13001",
language = "English",
volume = "74",
pages = "330--332",
journal = "Psychiatry and Clinical Neurosciences",
issn = "1323-1316",
publisher = "Wiley-Blackwell",
number = "5",
}
SDG 3 すべての人に健康と福祉を